196 related articles for article (PubMed ID: 35642117)
1. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
Panda SP
Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
[TBL] [Abstract][Full Text] [Related]
2. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
3. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
5. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Deacon CF
Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
[TBL] [Abstract][Full Text] [Related]
7. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
8. Update on incretin hormones.
Phillips LK; Prins JB
Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.
Zakaria EM; Tawfeek WM; Hassanin MH; Hassaballah MY
Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1357-1372. PubMed ID: 35945358
[TBL] [Abstract][Full Text] [Related]
10. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes.
Dalle S; Burcelin R; Gourdy P
Cell Signal; 2013 Feb; 25(2):570-9. PubMed ID: 23159576
[TBL] [Abstract][Full Text] [Related]
11. Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
Ribeiro-Silva JC; Marques VB; Dos Santos L
Am J Physiol Cell Physiol; 2023 Oct; 325(4):C972-C980. PubMed ID: 37642237
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
13. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Campos C; Unger J
Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
[TBL] [Abstract][Full Text] [Related]
14. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
15. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
17. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
18. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 Receptor Blockade Reduces Stimulated Insulin Secretion in Fasted Subjects With Low Circulating GLP-1.
Gray SM; Hoselton AL; Krishna R; Slentz CA; D'Alessio DA
J Clin Endocrinol Metab; 2022 Aug; 107(9):2500-2510. PubMed ID: 35775723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
